Disruptive Technology Channel
Cancer therapies and treatments are among the biggest markets in the broader biotechnology sector, and genomics is one of the preferred avenues for that exposure.
Cancer therapies and treatments are among the biggest markets in the broader biotechnology sector, and genomics is one of the preferred avenues for that exposure.
With the 10-year U.S. Treasury yield hovering below 1% and Federal Reserve Chairman Jerome Powell...
Investors could be forgiven to think there was no reason to invest outside of the U.S. for the...